Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Long-term Iron Absorption and Loss in Women

28 september 2026 uppdaterad av: Tippawan Pongcharoen, Mahidol University

Long-term Iron Absorption and Loss in Overweight/Obese Thai Middle-aged Women

Obese people typically have chronic low-grade inflammation. Based on short-term studies, this inflammation could affect the absorption, utilization, storage, and mobilization of iron, and individuals with inflammation might develop iron deficiency (ID) and anemia when inadequacy of iron intake is presented. The double burden of malnutrition is nowadays emerging as a major public health concern in many countries, including Thailand. Understanding the association of chronic inflammation among people with overweight or obesity (OW/OB) with long-term iron absorption and loss is important for developing appropriate policies and programs to promote iron balance and, consequently, optimal iron status and health outcomes. Since previous reports among Thai women showed a high prevalence of OW/OB and anemia, this study will be conducted to determine the long-term iron absorption and loss among OW/OB free-living women using the iron isotope dilution method.

Studieöversikt

Status

Rekrytering

Detaljerad beskrivning

  1. Research Objective To study iron absorption, loss, and long-term iron gain in overweight or obese middle-aged Thai women compared with normal-weight middle-aged Thai women.
  2. Research Methodology 2.1 Study design: This study is a longitudinal study comparing long-term iron absorption and loss between overweight or obese middle-aged Thai women and normal-weight middle-aged Thai women.

2.2 Study population: The study population consists of 64 women aged 40-50 years, divided into two groups: 32 overweight or obese women, and 32 normal-weight women.

2.3 Research Procedures 2.3.1 Before data collection: The research protocol is submitted for approval to the Central Institutional Review Board, Mahidol University. All data collectors will be trained prior to fieldwork. Upon receiving ethical approval, recruitment posters will be used to invite participants.

Screening process:

  1. Interested individuals meeting preliminary eligibility criteria will be informed about study details, sign informed consent, and schedule the first visit for screening and blood collection.

  2. Visit 1 (Screening):

    • Collect demographic and health history, measure weight, height, and body composition.
    • Collect 5 mL blood sample for Hb, SF, CRP, AGP, and hemoglobin typing.
    • Perform urine pregnancy test.
    • Administer one 400 mg albendazole tablet to prevent parasitic infection.

Iron isotope administration and follow-up:

2.3.2 Eligible participants will return within 1-2 weeks for the second visit.

Visit 2 (Month 0; M0):

Participants will consume a 15 mg ⁵⁷Fe isotope solution followed by 100 mg vitamin C drink, then fast for 3 hours.

A snack (plain yogurt and water) will be provided 1.5 hours after ingestion. A 24-hour dietary recall and semi-quantitative food frequency questionnaire (FFQ) will be conducted, with two additional 24-hour recalls by phone (2 weekdays and 1 weekend day).

Participants will then enter a 1-year equilibration period, recording illness and menstrual data monthly. The research team will monitor via LINE or email.

Visit 3 (Month 9; M9):

Collect fasting blood (5 mL) for Hb, glucose, HbA1c, and lipid profile; measure weight, BP, and conduct 24-hour recall (plus two by phone).

Visit 4 (After 1 year; WK0):

Collect fasting blood (10 mL) for Hb, SF, TfR, CRP, AGP, erythrocyte isotopic enrichment.

Measure weight, body composition, pregnancy test, and dietary recalls (3 days) and FFQ.

Visits 5-7 (WK8, WK16, WK24):

For eligible participants, repeat blood tests (7 mL) for Hb, SF, TfR, CRP, AGP, isotopic enrichment, anthropometry, pregnancy test, 3-day dietary recalls, and FFQ.

2.4 Research Instruments

  1. General information and medical history questionnaire, 24-hour dietary recall, and FFQ.

  2. Illness and menstrual record forms.

  3. Anthropometry and clinical measures:

    • Weight: InBody digital scale
    • Height: Harpenden stadiometer
    • Body composition: Bioelectrical Impedance Analyzer (BIA; InBody)
    • Blood pressure: Omron digital sphygmomanometer
  4. Laboratory analyses:

    • Hb: Complete Blood Count (CBC) using flow cytometry
    • SF, TfR, CRP, AGP: ELISA (SFa calculated from SF, CRP, AGP)
    • Hemoglobin typing: Capillary electrophoresis
    • Fasting glucose: Enzymatic method
    • HbA1c: Turbidimetric inhibition immunoassay
    • Lipids: Enzymatic colorimetric and homogeneous methods
    • Iron isotopes: Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 2.5 Data Analysis Nutrient intake (energy, carbohydrate, protein, fat, iron, zinc, calcium, vitamin C, vitamin A, and fiber) will be calculated using INMUCAL software.

Dietary patterns will be analyzed using Principal Component Analysis (PCA).

The average iron absorption (Fe_abs) over the study period will be calculated as:

Feabs=kabs×FetotalFe_{abs} = k_{abs} \times Fe_{total}Feabs=kabs×Fetotal where Fe_total is the total body iron at the midpoint estimated from the regression of Fe_total over time, and k_abs is the fractional iron absorption rate derived from the slope of the regression line of ln(⁵⁷Fe) vs. time.

Average iron loss (Fe_loss) is calculated similarly:

Feloss=kloss×FetotalFe_{loss} = k_{loss} \times Fe_{total}Feloss=kloss×Fetotal

Iron gain (Fe_gain) is calculated as:

Fegain=Feabs-FelossFe_{gain} = Fe_{abs} - Fe_{loss}Fegain=Feabs-Feloss Differences between groups in general characteristics, biochemical parameters, and iron absorption/loss slopes will be tested using Independent t-test or Mann-Whitney U-test, as appropriate.

A Linear Mixed-Effects Model will be used to analyze group differences in longitudinal changes of iron absorption, loss, and gain.

Statistical significance will be set at p < 0.05.

Studietyp

Observationell

Inskrivning (Beräknad)

64

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

  • Namn: Aree Prachansuwan, Ph.D.
  • Telefonnummer: +66890060602

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

40 år till 50 år (Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Kvinna

Testmetod

Icke-sannolikhetsprov

Studera befolkning

The study population will consist of 64 women aged 40-50 years, divided into two groups: 32 participants who are overweight or obese, and 32 participants with normal weight.

Beskrivning

Inclusion Criteria:

  • Normal weight group

    1. Aged 40-50 years
    2. Normal weight (BMI 18.5-22.9 kg/m²)
    3. Hb ≥12.0 g/dL and inflammation-adjusted SFa <50.0 µg/L
    4. CRP <5.0 mg/L
    5. Normal hemoglobin typing
    6. Plans to reside in the study area for >2 years
  • Overweight/obese group

    1. Aged 40-50 years
    2. Overweight or obese [Body Mass Index (BMI) ≥25.0 kg/m²] - the BMI cut-off follows the agreement of countries under the Coordinated Research Project (CRP) E43038 "Using the iron isotope dilution technique to assess the influence of inflammation on long-term iron absorption and loss," supported by the IAEA
    3. Hemoglobin (Hb) ≥12.0 g/dL and inflammation-adjusted serum ferritin (SFa) <50.0 µg/L
    4. C-reactive protein (CRP) between 5.0-25.0 mg/L
    5. Normal hemoglobin typing
    6. Plans to reside in the study area for >2 years

Exclusion Criteria:

  • Normal weight group

    1. Having serious medical conditions such as cancer, chronic kidney disease, chronic liver disease, or chronic heart failure
    2. Having metabolic NCDs (e.g., diabetes, hyperlipidemia, hypertension) requiring hospitalization
    3. Pregnant, breastfeeding, or planning pregnancy during the study
    4. Chronic infectious disease (e.g., tuberculosis, AIDS)
    5. Regular use of anti-inflammatory or other medications (except contraceptives and acne medication)
    6. Taking vitamin or mineral supplements during or within two weeks prior to the study
    7. Participating in a weight-loss program
    8. Known intolerance to iron supplements (e.g., vomiting, diarrhea, abdominal pain, bloating, nausea, or allergic reactions such as rash, breathing difficulty, chest tightness, facial or lip swelling)
    9. Blood transfusion, blood donation, or significant blood loss during the study or within 6 months before enrollment
    10. Heavy menstrual bleeding (>80 mL/day, calculated from menstrual record)
  • Overweight/obese group

    1. Obesity class II (BMI ≥35.0 kg/m²) with high health risk
    2. Having serious medical conditions such as cancer, chronic kidney disease, chronic liver disease, or chronic heart failure
    3. Having metabolic noncommunicable diseases (e.g., diabetes, hyperlipidemia, hypertension) requiring hospitalization
    4. Pregnant, breastfeeding, or planning pregnancy during the study
    5. Chronic infectious disease (e.g., tuberculosis, AIDS)
    6. Regular use of anti-inflammatory or other medications (except contraceptives and acne medication)
    7. Taking vitamin or mineral supplements during or within two weeks prior to the study
    8. Participating in a weight-loss program
    9. Known intolerance to iron supplements (e.g., vomiting, diarrhea, abdominal pain, bloating, nausea, or allergic reactions such as rash, breathing difficulty, chest tightness, facial or lip swelling)
    10. Blood transfusion, blood donation, or significant blood loss during the study or within 6 months before enrollment
    11. Heavy menstrual bleeding (>80 mL/day, calculated from menstrual record)

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Normal weight

BMI 18.5-22.9 kg/m2

Overweight or obesity

BMI 25-35 kg/m2

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Mean long-term iron absorption (Fe abs)
Tidsram: Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24).

Calculated over the duration of the study as follows: Fe abs = k abs x Fe total Where Fe total is the total body iron at the midpoint, calculated from the linear regression of Fe total versus time across each measurement point; and k abs is the fraction of total body iron absorbed per unit of time (derived from the slope of the linear regression equation of ln 57 Fe versus time).

57 Fe isotope will be measured using Inductively Coupled Plasma Mass Spectrometry (ICP-MS).

Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24).
Mean long-term iron loss (Fe loss)
Tidsram: Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Calculated in the same manner as iron absorption: Fe loss = k loss x Fe total Where k loss is the fraction of total body iron lost per unit of time.

Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Iron gain (Fe gain)
Tidsram: Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Calculated as net iron balance: Fe gain = Fe abs - Fe loss

Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Weight (kg)
Tidsram: Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Weight will be measured in kg (to the nearest 0.1 kg) using an Inbody digital weighing scale.

Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Height (cm)
Tidsram: Visit 1 (Screening)

Height will be measured to the mearest 0.1 cm using a Harpenden stadiometer.

Visit 1 (Screening)
Body Mass Index (BMI, kg/m²)
Tidsram: Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

BMI will be calculatedn body weight in kilograms divided by height in meters squared.

Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Body composition (fat mass)
Tidsram: Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 7 (WK24)

Body composition (fat mass) will be measured using the Bioelectrical Impedance Analyzer (BIA; InBody).

Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 7 (WK24)
Nutrient intakes
Tidsram: Visit 2 (Month 0), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Nutrient intakes (energy, carbohydrate, protein, fat, iron, zinc, calcium, vitamin C, vitamin A, and fiber) will be calculated from 3-day 24-hr dietary recalls using INMUCAL software.

Visit 2 (Month 0), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Dietary pattern
Tidsram: Visit 2 (Month 0), Visit 4 (after 1 year; WK0), Visits 7 (WK24)

Dietary patern from FFQ will be analyzed using the Principal Component Analysis (PCA)

Visit 2 (Month 0), Visit 4 (after 1 year; WK0), Visits 7 (WK24)
Hemoglobin (Hb, g/L)
Tidsram: Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Hb concentration will be assessed using flow cytometry

Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Serum ferritin (SF, µg/L)
Tidsram: Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

SF will be measured using Enzyme-linked immunosorbent assay (ELISA)

Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
serum transferrin receptor (sTfR µg/L)
Tidsram: Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

sTfR will be assessed using ELISA

Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
c-reactive protein (CRP, mg/L)
Tidsram: Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

CRP will measured using ELISA

Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
alpha-1 acid glycoprotein (AGP, g/L)
Tidsram: Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

AGP will be measured using ELISA

Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Glycated hemoglobin (HbA1c, %)
Tidsram: Visit 3 (Month 9)

HbA1c wil be measured by Turbidimetric inhibition immunoassay

Visit 3 (Month 9)
Lipid profile
Tidsram: Visit 3 (Month 9)

Lipid profile (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides) will be measured using Enzymatic colorimetric and homogeneous methods.

Visit 3 (Month 9)
Blood pressure (BP, mmHg)
Tidsram: Visit 3 (Month 9)

BP will be measured using Omron digital sphygmomanometer

Visit 3 (Month 9)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Veronica LOPEZ TEROS, Ph.D., Internation Atomic Energy Agency

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

8 maj 2025

Primärt slutförande (Beräknad)

31 december 2027

Avslutad studie (Beräknad)

31 augusti 2028

Studieregistreringsdatum

Först inskickad

6 augusti 2026

Först inskickad som uppfyllde QC-kriterierna

28 september 2026

Första postat (Faktisk)

2 oktober 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

2 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

28 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

IPD-planbeskrivning

There has been ongoing discussion regarding collaboration on data analysis and publication among countries that have conducted studies supported by the International Atomic Energy Agency (IAEA).

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera